Assessing Response in Bone Metastases in Prostate Cancer with Diffusion Weighted MRI

Overview

Journal Eur Radiol

Specialty Radiology

Date 2011 Jun 29

PMID 21710270

Citations 28

Authors

C Messiou

D J Collins

S Giles

J S de Bono

D Bianchini

N M de Souza

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine whether changes in ADC of bone metastases secondary to prostate carcinoma are significantly different in responders compared with progressors on chemotherapy.

Methods: Twenty-six patients with known bone metastases secondary to prostate carcinoma underwent diffusion-weighted MRI of the lumbar spine and pelvis at baseline and 12 weeks following chemotherapy. RECIST assessment of staging CT and PSA taken at the same time points were used to classify patients as responders, progressors or stable. ADC (from b = 0,50,100,250,500,750 smm⁻²) and ADC(slow) (from b = 100,250,500,750 smm⁻²) were calculated for up to 5 lesions per patient.

Results: Mean ADC/ADC(slow) in lesions from responders and progressors showed a significant increase. Although the majority of lesions demonstrated an ADC/ADC(slow) rise, some lesions in both responders and progressors demonstrated a fall in ADC beyond the limits of reproducibility.

Conclusions: Mean ADC is not an appropriate measure of response in bone metastases. The heterogeneity of changes in ADC is likely to be related to the composition of bone marrow with changes that have opposing effects on ADC.

Citing Articles

The Role of CT and MR Imaging in Stereotactic Body Radiotherapy of the Spine: From Patient Selection and Treatment Planning to Post-Treatment Monitoring.

Azadbakht J, Condos A, Haynor D, Gibbs W, Jabehdar Maralani P, Sahgal A Cancers (Basel). 2024; 16(21).

PMID: 39518130 PMC: 11545634. DOI: 10.3390/cancers16213692.

Multiparametric Whole-Body MRI: A Game Changer in Metastatic Prostate Cancer.

Cattabriga A, Renzetti B, Galuppi F, Bartalena L, Gaudiano C, Brocchi S Cancers (Basel). 2024; 16(14).

PMID: 39061171 PMC: 11274871. DOI: 10.3390/cancers16142531.

Diffusion-Weighted MRI for Treatment Response Assessment in Osteoblastic Metastases-A Repeatability Study.

Eveslage M, Rassek P, Riegel A, Maksoud Z, Bauer J, Gorlich D Cancers (Basel). 2023; 15(15).

PMID: 37568573 PMC: 10417276. DOI: 10.3390/cancers15153757.

Multidisciplinary management of spinal metastases: what the radiologist needs to know.

Bahouth S, Yeboa D, Ghia A, Tatsui C, Alvarez-Breckenridge C, Beckham T Br J Radiol. 2022; 95(1138):20220266.

PMID: 35856792 PMC: 9815745. DOI: 10.1259/bjr.20220266.

Which Parameter Influences Local Disease-Free Survival after Radiation Therapy Due to Osteolytic Metastasis? A Retrospective Study with Pre- and Post-Radiation Therapy MRI including Diffusion-Weighted Images.

Lee J, Yoon Y, Lee J, Kim H J Clin Med. 2022; 11(1).

PMID: 35011847 PMC: 8745622. DOI: 10.3390/jcm11010106.

References

Reese T, Heid O, Weisskoff R, Wedeen V . Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refocused spin echo. Magn Reson Med. 2003; 49(1):177-82. DOI: 10.1002/mrm.10308. View

Clamp A, Danson S, Nguyen H, Cole D, Clemons M . Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 2004; 5(10):607-16. DOI: 10.1016/S1470-2045(04)01596-7. View

Messiou C, Collins D, Morgan V, deSouza N . Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol. 2011; 21(8):1713-8. DOI: 10.1007/s00330-011-2116-4. View

Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M . Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004; 22(4):275-82. View

Ballon D, Watts R, Dyke J, Lis E, Morris M, Scher H . Imaging therapeutic response in human bone marrow using rapid whole-body MRI. Magn Reson Med. 2004; 52(6):1234-8. PMC: 2408689. DOI: 10.1002/mrm.20291. View

Morris M, Akhurst T, Larson S, Ditullio M, Chu E, Siedlecki K . Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005; 11(9):3210-6. PMC: 2040333. DOI: 10.1158/1078-0432.CCR-04-2034. View

Morris M, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K . Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002; 59(6):913-8. DOI: 10.1016/s0090-4295(02)01509-1. View

Bubley G, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M . Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17(11):3461-7. DOI: 10.1200/JCO.1999.17.11.3461. View

Rozel S, Galban C, Nicolay K, Lee K, Sud S, Neeley C . Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem. 2009; 107(1):58-64. PMC: 4293017. DOI: 10.1002/jcb.22056. View

10.

Scher H . Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer. 2003; 97(3 Suppl):758-71. DOI: 10.1002/cncr.11151. View

11.

Mundinger A, Wiesmeier B, Dinkel E, Helwig A, Beck A, Schulte Moenting J . Quantitative image analysis of vertebral body architecture--improved diagnosis in osteoporosis based on high-resolution computed tomography. Br J Radiol. 1993; 66(783):209-13. DOI: 10.1259/0007-1285-66-783-209. View

12.

Park S, Kim S, Park B, Suh K, Lee J, Park C . Three-dimensional osseous micro-architecture of the distal humerus: implications for internal fixation of osteoporotic fracture. J Shoulder Elbow Surg. 2009; 19(2):244-50. DOI: 10.1016/j.jse.2009.08.005. View

13.

Reischauer C, Froehlich J, Koh D, Graf N, Padevit C, John H . Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations. Radiology. 2010; 257(2):523-31. DOI: 10.1148/radiol.10092469. View

14.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

15.

Lee K, Sud S, Meyer C, Moffat B, Chenevert T, Rehemtulla A . An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res. 2007; 67(8):3524-8. DOI: 10.1158/0008-5472.CAN-06-4236. View

16.

Lee K, Bradley D, Hussain M, Meyer C, Chenevert T, Jacobson J . A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia. 2007; 9(12):1003-11. PMC: 2134897. DOI: 10.1593/neo.07954. View